4sc Discovery Gmbh

Topotarget Germany Ag

Karlsruher Institut Fur Technologie

Bernd Hentsch

Michael Gassen

Alexandra Matzke

Helmut Ponta

Rolf Krauss

Juergen Kraus

Veronique Orian-Rousseau

Sylvia E Schwarz

Alexander B Maurer

Elke Martin

Adam-Spencer Vincek

Sascha Hövelmann

Sascha Hoevelmann

Monika Raab

Peter A Herrlich

Jan Adam

The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.

Compounds as histone deacetylase inhibitors

Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of crucial genes which predispose a person with this condition to develop the disease phenotype. Thus, such compounds can be used for a suppressive therapeutic approach&#x2014;the SUPPRESSION THERAPY&#x2014;in order to inhibit or delay the onset or progression of the genetically predisposed disorder. Furthermore, a clinically used medicament can be manufactured for the SUPPRESSION THERAPY of such inherited predisposing conditions.

Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions

Growing community of inventors

Duisburg, Germany

Bernd Hentsch